King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127: 289−299.

A wide range of medications classified as tyrosine kinase inhibitors, monoclonal antibodies, mammalian target of rapamycin inhibitors, radiopharmaceuticals, selective oestrogen receptor modulators, and immunosuppressants have also been found to be implicated in MRONJ.

The link between medication-related osteonecrosis of the jaw (MRONJ) and bone modulating drugs, such as bisphosphonates and denosumab is well established. The development of novel medications used in the treatment of cancer, as well as autoimmune and bone conditions has led to further cases of MRONJ being reported. However, in addition to this group of medications, increasing numbers of new agents in cancer therapy, such as antiangiogenic agents, have also been implicated in the development of MRONJ. The authors mention that as these newer agents with similar mechanisms are routinely used, the numbers of reported cases will likely rise. A wide range of medications classified as tyrosine kinase inhibitors, monoclonal antibodies, mammalian target of rapamycin inhibitors, radiopharmaceuticals, selective oestrogen receptor modulators, and immunosuppressants have been found to be implicated in MRONJ. The authors emphasised the importance of oral health care providers being aware of these new medications.